The AHA today urged the Health Resources and Services Administration to implement its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers without delay. “Delaying the implementation of the ceiling price and CMPs an additional nine months – from Oct. 1, 2017 to July 1, 2018 – is not justified given the exhaustive development process that has occurred,” wrote AHA Executive Vice President Tom Nickels. AHA also reiterated its support for HRSA’s decision to codify its “penny pricing policy” to strengthen oversight of 340B ceiling prices and discourage manufacturers from raising prices faster than inflation. “While this policy has been in place for many years, drug manufacturers have not applied it consistently,” AHA said. “…In addition, we look forward to working with HRSA on further guidance on the 340B ceiling reporting system and how 340B hospitals and covered entities can access ceiling price information to establish instances of manufacturer overcharges.”

Related News Articles

Headline
The AHA July 16 filed an amicus brief in the U.S. District Court for the District of Colorado in defense of the state’s 340B contract pharmacy law prohibiting…
Headline
The U.S. District Court for the Eastern District of Missouri July 11 granted a motion by the state to dismiss claims by AbbVie that the state’s 340B contract…
Headline
The AHA July 8 wrote in opposition to the “Patient Access to Higher Quality Health Care Act” (H.R. 4002), which would repeal current law banning the creation…
Headline
The AHA July 3 released the Health Care Plan Accountability Update for the second quarter of 2025. The update covers the latest developments in Medicare…
Headline
The Departments of Justice and Health and Human Services today announced the creation of the DOJ-HHS False Claims Act Working Group to combat health care fraud…
Headline
The U.S. District Court for the Middle District of Tennessee June 30 denied a motion for a preliminary injunction by AbbVie in its lawsuit against the state’s…